CarterCASkoutakisVASpiroTEWestMEToomsREJoeRHEnoxaparin: The low-molecular-weight heparin for prevention of postoperative thromboembolic complications. Ann Pharmacother1993; 27: 1223–30.
2.
ClagettGPAndersonFALevineMNSalzmanEWWheelerHB. Prevention of venous thromboembolism. Chest1992; 102 (suppl):391S–407S.
3.
HullRRaskobGPineoGRosenbloomDEvansWMalloryTA comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med1993; 329: 1370–6.
4.
LevineMNPlanesAHirschJGoodyearMVochelleNGentM. The relationship between anti-Factor Xa level and clinical outcome in patients receiving enoxaparin low molecular weight heparin to prever deep vein thrombosis after hip replacement. Thromb Haemost1989; 62: 940–4.
5.
KandrotasRJ. Low-molecular-weight heparins: Do good things really come in small packages?Ann Pharmacother1993; 27: 1270–1.
